Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sunshine Biopharma, Inc. (SBFM : NSDQ)

• Company Description    Sunshine Biopharma Inc. is a pharmaceutical company. It focused on the research, development and commercialization of oncology and antiviral drugs. Sunshine Biopharma Inc. is based in MONTREAL. Number of Employees: 50

• Price / Volume Information    Yesterday's Closing Price: $0.48 Daily Weekly Monthly 20 Day Moving Average: 38,898,720 shares Shares Outstanding: 5.01 (millions) Market Capitalization: $2.41 (millions) Beta: 1.37 52 Week High: $2.43 52 Week Low: $0.28 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -51.38% -53.76% 12 Week -60.87% -63.83% Year To Date -60.87% -61.40%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 333 LAS OLAS WAY CU4 SUITE 433 - FORT LAUDERDALE,FL 33301 USA ph: 954-330-0684 fax: - investors@sunshinebiopharma.com https://sunshinebiopharma.com

• General Corporate Information    Officers Steve N. Slilaty - Chief Executive Officer Camille Sebaaly - Chief Financial Officer David Natan - Director Andrew Keller - Director Rabi Kiderchah - Director Peer Information Sunshine Biopharma, Inc. (CORR.) Sunshine Biopharma, Inc. (RSPI) Sunshine Biopharma, Inc. (CGXP) Sunshine Biopharma, Inc. (BGEN) Sunshine Biopharma, Inc. (GTBP) Sunshine Biopharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 867781700 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 5.01 Most Recent Split Date: 8.00 (0.05:1) Beta: 1.37 Market Capitalization: $2.41 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.11 Price/Cash Flow: - Price / Sales: 0.07 EPS Growth vs. Year Ago Period: 43.18% vs. Previous Quarter: 45.65% Sales Growth vs. Year Ago Period: -9.12% vs. Previous Quarter: -5.69% ROE 03/31/26 - -27.75 12/31/25 - -27.14 09/30/25 - -24.96 ROA 03/31/26 - -21.57 12/31/25 - -21.14 09/30/25 - -19.46 Current Ratio 03/31/26 - 4.22 12/31/25 - 4.17 09/30/25 - 4.20 Quick Ratio 03/31/26 - 1.98 12/31/25 - 2.08 09/30/25 - 2.09 Operating Margin 03/31/26 - -18.45 12/31/25 - -17.86 09/30/25 - -16.06 Net Margin 03/31/26 - -18.45 12/31/25 - -17.86 09/30/25 - -16.06 Pre-Tax Margin 03/31/26 - -16.84 12/31/25 - -16.40 09/30/25 - -17.44 Book Value 03/31/26 - 4.30 12/31/25 - 4.69 09/30/25 - 4.93 Inventory Turnover 03/31/26 - 1.77 12/31/25 - 1.84 09/30/25 - 1.99 Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©